Acadia Pharmaceuticals | ACAD - Operating Expenses


Acadia Pharmaceuticals reported $272.68M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Prothena USD 27.23M 14.95M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026